BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
October 02, 2024 07:00 ET
|
BioStem Technologies, Inc.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
September 30, 2024 07:00 ET
|
BioStem Technologies, Inc.
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
August 29, 2024 07:00 ET
|
BioStem Technologies, Inc.
BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
August 21, 2024 07:00 ET
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje®
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
August 12, 2024 16:14 ET
|
Biostem Technologies
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
August 05, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024